Shire's Alagille syndrome drug fails Phase II trial
This article was originally published in Scrip
Executive Summary
Shire's Phase II IMAGO trial of SHP625 in 20 pediatric patients with Alagille syndrome (ALGS) has failed to meet its primary or secondary endpoints.